Immunophenotypic features of PTCL-NOS
| Immunophenotype . | PTCL-NOS, % (n/N) . | Lymphoepithelioid PTCL, % (n/N) . |
|---|---|---|
| CD2 | 86 (211/244) | 100 (13/13) |
| CD3E | 93 (238/255) | 88 (14/16) |
| CD4 | 66 (140/213) | 64 (9/14) |
| CD5 | 69 (170/245) | 87 (13/15) |
| CD8 | 19 (48/250) | 44* (7/16) |
| CD30 | 32 (69/217) | 12* (2/16) |
| CD56 | 6 (13/219) | 8 (1/13) |
| TCR-β | 38 (72/190) | 91* (10/11) |
| TIA-1 | 32 (62/195) | 46 (6/13) |
| EBER | ||
| 1-4+ | 30 (67/222) | 31 (4/13) |
| 3-4+ | 14 (30/222) | 0 (0/13) |
| Immunophenotype . | PTCL-NOS, % (n/N) . | Lymphoepithelioid PTCL, % (n/N) . |
|---|---|---|
| CD2 | 86 (211/244) | 100 (13/13) |
| CD3E | 93 (238/255) | 88 (14/16) |
| CD4 | 66 (140/213) | 64 (9/14) |
| CD5 | 69 (170/245) | 87 (13/15) |
| CD8 | 19 (48/250) | 44* (7/16) |
| CD30 | 32 (69/217) | 12* (2/16) |
| CD56 | 6 (13/219) | 8 (1/13) |
| TCR-β | 38 (72/190) | 91* (10/11) |
| TIA-1 | 32 (62/195) | 46 (6/13) |
| EBER | ||
| 1-4+ | 30 (67/222) | 31 (4/13) |
| 3-4+ | 14 (30/222) | 0 (0/13) |
P < .05 vs all other PTCL-NOS.